Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Albanese government, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Queensland
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Albanese government, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.5 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.7 for that window. We currently track 1 Biotech story that mention Queensland, all published on August 1, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Queensland. Shared-story counts are live from our verified record — not editorial picks.
Australia's shift to financial biodiversity offsets, with 90% of Queensland obligations paid in cash, accelerates habitat loss that could eliminate undiscovered medicinal compounds, posing a long-term risk to biotech and pharmaceutical companies reliant on natural genetic resources.